1 	|BT| (S (NP (JJ Other) (NN expression) (NN alteration)) (VP (VBN observed) (S (NP (JJ arsenic-treated) (JJ male) (NN mouse) (JJ newborn) (NN liver)) (VP (VBD included) (SBAR (S (NP (NP (NN overexpression) (NNS cdk-inhibitors) (NN stress) (NN response) (NN gene)) (PP (VBG including) (NP (VBN increased) (NN expression) (NN metallothionein-1)))) (VP (VBD decreased) (NP (NN expression) (NN betaine-homocysteine) (NN methyltransferase) (NN thioether) (NN S-methyltransferase))))))))) |ET| |BS|6:G05.360.340.024.340 11:B01.050.150.900.649.865.635.505.500 52:E02 242:A03.620 978:D08.811.913.696.620.682.700.646.500 1158:D01.268.513.249 1462:D08.811.913.555.500.175 1463:D08.811.913.555.500 1464:D01.248.497.158.874 1465:M01.060.703.520 1466:D12.776.556.670|ES| 9:1 19:1 47:1 52:1 115:1 152:1 202:1 261:1 494:1 561:1 836:1 951:1 1402:1 1528:1 2522:1 2655:1 5375:1 5376:1 5377:1 5378:1 5379:1 5380:1 5381:1 5382:1
1 	|BT| (S (NP (DT A) (JJ recent) (NN study)) (VP (VBD revealed) (SBAR (S (NP (NP (JJ long-term) (NN exposure)) (ADJP (RB relatively) (JJ low-dose)) (NN DEHP) (PRN (-LRB- -LRB-) (NP (CD 0.05) (NN %)) (-RRB- -RRB-))) (VP (VBD caused) (NP (NP (NN liver) (NN tumor)) (PP (VBG including) (NP (NP (JJ hepatocellular) (NN carcinoma)) (, ,) (NP (JJ hepatocellular) (NN adenoma)) (, ,) (NP (NP (NP (NP (ADJP (NP (JJ chologiocellular) (NN carcinoma)) (JJR higher)) (NN incidence) (NN Ppar) (JJ alpha-null) (NN mouse)) (PRN (-LRB- -LRB-) (NP (CD 25.8) (NN %)) (-RRB- -RRB-))) (NP (JJ wild-type) (NN mouse))) (PRN (-LRB- -LRB-) (NP (CD 10.0) (NN %)) (-RRB- -RRB-))))))))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 29:B01.050.050.136.500.500 104:C04.557.470.200.025.255 265:C04.557.470.200 434:E05.318.308.985.525.375 515:C04.588.274.623 536:D12.776.826.239.500 849:G08.686.785.760.769.490.500 911:D02.241.223.805.250 1194:C04.557.470.035.120|ES| 2:1 7:1 8:1 10:1 14:1 19:1 42:1 52:1 69:1 131:1 170:1 275:1 303:1 304:1 369:1 561:1 659:1 836:1 1511:1 1953:1 2506:1 3049:1 3205:1 3546:1 3849:1 3924:1 5383:1 5384:1 5385:1 5386:1 5387:1
1 	|BT| (S (NP (NP (NN Activation) (JJ nonsteroidal) (JJ anti-inflammatory) (JJ drug-activated) (NN gene-1)) (PP (IN via) (NP (JJ extracellular) (JJ signal-regulated) (NN kinase) (CD 1/2) (JJ mitogen-activated) (NN protein) (NN kinase)))) (VP (VBD revealed) (NP (JJ isochaihulactone-triggered) (JJ apoptotic) (NN pathway) (NP (JJ human) (NN lung) (NN cancer) (NN A549) (NN cell))))) |ET| |BS|39:G04.299.139.160 41:A11 55:B01.050.150.900.649.801.400.112.400.400 264:G05.355.315.800 469:D08.811.913.696 477:D08.811.913.696.620.682.700.567.249 573:N05.715.350.200.650 796:D27.505.696.663.850.014.040.500|ES| 4:1 18:1 19:1 36:1 87:1 94:1 275:1 328:1 364:1 383:1 470:1 596:1 1707:1 1859:1 2223:1 2795:1 3046:1 3295:1 4812:1 4966:1 4978:1 5388:1
1 	|BT| (S (S (S (ADVP (RB Additionally)) (, ,) (NP (NN co-treatment) (NN RV) (NN erlotinib)) (VP (VBD repressed) (NP (NP (NN expression) (JJ anti-apoptosis) (NN protein)) (, ,) (NP (NN survivin) (NN Mcl-1)))) (, ,)) (IN whereas) (NP (VBN promoted) (NN p53) (NN PUMA) (NN expression) (NN caspase) (CD 3) (NN activity)))) |ET| |BS|2:G05.360.340.024.340.375.249.385 52:E02 906:D08.811.277.656.262.500.126.350.300 1042:Z01.107.757.284 1467:B01.050.150.900.649.147.354.630 1468:E01.370.386.700.485.750.275.650 1469:D12.644.360.075|ES| 2:1 4:1 12:1 19:1 115:1 372:1 399:1 466:1 862:1 1912:1 2229:1 2342:1 4068:1 4796:1 5312:1 5389:1 5390:1 5391:1 5392:1
1 	|BT| (NP (NP (JJ Altered) (NN expression) (NN c-myc)) (, ,) (NP (NN p16) (NN p27) (NN rat) (NN colon) (NN tumor) (NN reversal) (JJ short-term) (NN treatment) (JJ chemopreventive) (NN agent))) |ET| |BS|51:C04.588.274.476.411.307.180 52:E02 203:G05.360.340.024.340.375.249.375 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 833:D27.505.696.706.018 849:G08.686.785.760.769.490.500|ES| 2:1 7:1 19:1 113:1 115:1 455:1 546:1 728:1 849:1 971:1 1124:1 1313:1 1946:1 3022:1 3770:1
1 	|BT| (S (NP (NNP Assessment) (NN effect) (NN betaine) (NN p16) (NN c-myc) (NN DNA) (NN methylation) (NN mRNA) (NN expression) (NN chemical)) (VP (VBD induced) (NP (NN rat) (NN liver) (NN cancer) (NN model)))) |ET| |BS|111:D13.444.735.544 203:G05.360.340.024.340.375.249.375 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 366:G02.111.087.029.538.161 743:D02.092.877.883.077 838:E05.599.495|ES| 18:1 19:1 72:1 75:1 81:1 115:1 325:1 412:1 455:1 666:1 836:1 849:1 1313:1 2124:1 2636:1 5393:1
1 	|BT| (NP (NP (DT Both) (NP (NNP BaA) (NNPS MeBaAs) (JJ similar) (NN effect) (NN expression) (NN cytochrome) (NN P450) (NN 1B1) (JJ aldo-keto) (NN reductase) (NN 1C9) (NN rat) (NN liver) (JJ epithelial) (NN WB-F344) (NN cell)))) |ET| |BS|75:A11.436 242:A03.620 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 590:B01.050.050.199.520.760.200|ES| 19:1 75:1 94:1 96:1 115:1 127:1 332:1 836:1 849:1 2549:1 3276:1 3788:1 4678:1 5394:1 5395:1 5396:1 5397:1 5398:1
1 	|BT| (S (NP (NNP CAPE) (CC plus) (NNP DEN)) (VP (VBD diminished) (NP (NP (NN expression) (NN cytochrome) (VBN involved) (NN DEN) (NN bioactivation) (NN CYP2B1)) (VP (ADVP (RB well)) (NP (NP (NN expression) (NN regulator) (JJ oxidative) (NN stress) (NN glutathione) (NN reductase)) (, ,) (NP (NN GST-kappa) (NN GST-theta)) (, ,) (NP (NN cell) (NN cycle) (NN regulator)) (NP (NN p53))))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 7:D12.776 30:Z01.058.290.190.800 31:D08.811.520.224.800 155:G05.355.310 353:G04.299.134 716:G03.495.710 1470:D08.244.453.040.550 1471:D08.811.682.667.092 1472:D08.244|ES| 2:1 4:1 9:1 12:1 19:1 94:1 96:1 115:1 162:1 235:1 569:1 601:1 637:1 693:1 712:1 774:1 787:1 831:1 900:1 911:1 1719:1 1875:1 2332:1 2353:1 2522:1 2583:1 2744:1 3045:1 3146:1 3374:1 3788:1 4156:1 4350:1 4720:1 4888:1 5399:1 5400:1 5401:1 5402:1 5403:1 5404:1
1 	|BT| (S (NP (NN Coexpression) (NN K-rasVal12) (NN TAgWt)) (VP (VBP produce) (NP (NN dysplasia)))) |ET| |BS||ES| 19:1 203:1 1565:1 5405:1 5406:1 5407:1
1 	|BT| (S (NP (JJ Consistent) (NN finding) (, ,) (NN treatment) (NP (NP (NN protein) (NN kinase) (NN A)) (PRN (-LRB- -LRB-) (NP (NN PKA)) (-RRB- -RRB-))) (NN inhibitor)) (VP (VBD decreased) (NP (NN MMP2) (NN MMP9) (NN expression) (NN level) (JJ ADCY3-overexpressing) (NN cell)))) |ET| |BS|41:A11 52:E02 586:D08.811.277.656.300.480.205.360 1417:D08.811.277.656.300.480.205.352|ES| 2:1 4:1 10:1 14:1 19:1 69:1 94:1 115:1 202:1 249:1 380:1 470:1 546:1 927:1 3395:1 5408:1 5409:1 5410:1 5411:1
1 	|BT| (S (NP (NN Curcumin)) (VP (VBZ sensitizes) (NP (NP (JJ human) (JJ colorectal) (NN cancer) (NN xenograft) (JJ nude) (NN mouse) (NN gamma-radiation)) (VP (VBG targeting) (NP (JJ nuclear) (JJ factor-kappaB-regulated) (NN gene) (NN product)))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 30:Z01.058.290.190.800 31:D08.811.520.224.800 55:B01.050.150.900.649.801.400.112.400.400 88:B01.050.150.900.649.865.635.505.500.550.500 92:E04.936.764 93:A01.941.875 142:I01.880.604 210:D12.776.260.600 692:D02.455.326.146.485.222.222 816:G01.358.500.505.300 973:E05.393.335|ES| 9:1 17:1 18:1 19:1 36:1 52:1 265:1 266:1 616:1 675:1 1256:1 2062:1 3429:1 3430:1 3431:1
1 	|BT| (S (NP (NN DEN) (NN treatment)) (VP (VP (VBD increased) (NP (NP (NN expression) (NN gene)) (VP (VBN associated) (NP (JJ oxidative) (NN stress) (NN glutathione) (NN reductase))))) (, ,) (NP (NP (NN gene) (VBN involved) (NN cell) (NN cycle) (NN regulation)) (PP (VBG including) (NP (NP (NN p53)) (, ,) (NP (VBN modified) (NN cytochrome) (NN P450))))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 6:G05.360.340.024.340 52:E02 155:G05.355.310 716:G03.495.710 1079:D08.244.453 1259:G04.299.134.109 1471:D08.811.682.667.092|ES| 2:1 9:1 12:1 19:1 47:1 94:1 96:1 115:1 169:1 438:1 546:1 561:1 601:1 774:1 1875:1 2335:1 2522:1 2549:1 2583:1 2744:1 3788:1
1 	|BT| (NP (NP (NP (NN DEN) (NN treatment) (VBN modified) (NN expression) (CD 665) (NN gene)) (, ,) (NP (NP (NN CAPE)) (CC plus) (NP (NN DEN))) (VP (VBD induced) (NP (NN change) (CD 1371) (NN gene))))) |ET| |BS|6:G05.360.340.024.340 52:E02 155:G05.355.310|ES| 2:1 9:1 19:1 115:1 200:1 412:1 546:1 1875:1 2332:1 2335:1 4888:1 5412:1 5413:1
1 	|BT| (NP (NP (JJ Different) (NN mechanism) (JJ DEHP-induced) (JJ hepatocellular) (NN adenoma) (NN tumorigenesis) (JJ wild-type) (NN Ppar) (JJ alpha-null) (NN mouse))) |ET| |BS|29:B01.050.050.136.500.500 32:C04.697.098.500 33:C04.697.098 536:D12.776.826.239.500 911:D02.241.223.805.250 1194:C04.557.470.035.120|ES| 8:1 19:1 42:1 52:1 78:1 162:1 303:1 5384:1 5385:1 5414:1 5415:1
1 	|BT| (S (NP (NP (NN DNA) (NN binding) (NN activity) (JJ nuclear) (NN factor) (NN kappa) (NN B)) (PRN (-LRB- -LRB-) (NP (NN NF-kappaB)) (-RRB- -RRB-))) (VP (VBZ transactivates) (NP (NP (NP (NN miR-155) (NN gene)) (ADJP (ADVP (RB significantly)) (PRN (-LRB- -LRB-) (S (NP (NN P)) (VP (JJ =) (NP (CD 0.002)))) (-RRB- -RRB-))) (JJ elevated) (NN liver) (JJ nuclear) (NN extract) (NN mouse)) (VBN fed) (NNP CDAA) (NN diet)))) |ET| |BS|6:G05.360.340.024.340 11:B01.050.150.900.649.865.635.505.500 198:D13.444.308 210:D12.776.260.600 595:G07.203.650.240 596:E02.642.249 663:C16.320.565.398.500.330.500 1473:D20.777.351|ES| 9:1 10:1 14:1 19:1 52:1 124:1 185:1 311:1 399:1 581:1 666:1 714:1 756:1 763:1 836:1 1254:1 1256:1 1487:1 1911:1 2191:1 2426:1 2496:1 3184:1 3750:1 5066:1
1 	|BT| (FRAG (NP (NP (NP (NP (RB Early) (NN detection)) (JJ 2-amino-1-methyl-6-phenylimidazo) (-LRB- -LRB-) (JJ 4,5-b) (-RRB- -RRB-) (NN pyridine) (-LRB- -LRB-) (NN PhIP) (-RRB- -RRB-) (: -)) (VBN induced) (NN mutation)) (PP (IN within) (NP (NN Apc) (NN gene) (NN rat) (NN colon))))) |ET| |BS|18:G05.365.590 21:G05.360.340.024.340.375.249.050 46:A03.556.124.526.356 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 494:E01.390 744:D03.383.725|ES| 9:1 10:1 14:1 19:1 34:1 113:1 280:1 409:1 849:1 1023:1 2122:1 2638:1 2639:1 2640:1 2641:1 4135:1
1 	|BT| (S (ADVP (RB Finally)) (, ,) (NP (NN PhIP)) (VP (VBD appeared) (NP (NP (NP (JJ carcinogenic) (NN XPA)) (PRN (-LRB- -LRB-) (: -) (: /) (: -) (-RRB- -RRB-))) (NN mouse) (JJ subtoxic) (NNS dos)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 30:Z01.058.290.190.800 31:D08.811.520.224.800 279:D27.888.569.100|ES| 2:1 10:1 14:1 19:1 45:1 52:1 1929:1 2641:1 2653:1 3346:1 3836:1 5416:1 5417:1
1 	|BT| (S (ADVP (RB Finally)) (, ,) (VP (VBP demonstrate) (NP (NP (JJ NSAID-mediated) (JJ nucleolar) (NN translocation) (NN RelA)) (VP (VBN associated) (NP (NP (NN downregulation) (JJ NF-kappaB-driven) (NN transcription) (NN NF-kappaB) (NN target) (NN gene)) (, ,) (NP (NN ICAM-1))))))) |ET| |BS|6:G05.360.340.024.340 66:F01.658.293 85:G02.111.087.225 209:G02.111.087.847 210:D12.776.260.600 463:C23.550.210.870 796:D27.505.696.663.850.014.040.500 1325:D12.776.395.550.200.450|ES| 2:1 9:1 19:1 160:1 169:1 250:1 487:1 502:1 595:1 714:1 1618:1 1929:1 4732:1 5418:1 5419:1 5420:1
1 	|BT| (S (ADVP (RB Furthermore)) (, ,) (NP (NP (JJ stress-associated) (NN hormone)) (, ,) (NP (NN isoproterenol)) (, ,)) (VP (MD could) (VP (VP (VB increase) (NP (NN expression) (NN level) (`` ``) (NN stem) ('' ''))) (: -) (S (NP (NP (JJ related) (NN protein)) (, ,) (NP (NN CD44)) (, ,) (NP (NNP Nanog)) (, ,) (NP (NN Rex-1)) (, ,)) (VP (VBP induce) (NP (NN chemoresistance) (JJ gastric) (NN cancer) (NN cell))))))) |ET| |BS|7:D12.776 41:A11 161:D06.472 309:A18.024.937 1474:D02.033.100.291.439|ES| 2:1 4:1 18:1 19:1 40:1 86:1 94:1 115:1 182:1 243:1 249:1 334:1 542:1 908:1 1106:1 1282:1 1581:1 3268:1 3269:1 5421:1 5422:1 5423:1 5424:1
1 	|BT| (S (ADVP (RB Furthermore)) (, ,) (NP (NN UDCA)) (VP (VBD inhibited) (NP (NP (NN Cox-2) (NN induction) (JJ Ras-dependent)) (: -) (NP (JJ independent) (NN mechanism))))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550 122:C14.280.383 737:D04.808.105.225.272.962|ES| 2:1 19:1 62:1 162:1 334:1 365:1 736:1 2631:1 5425:1 5426:1
1 	|BT| (NP (NP (NP (JJ Genotype-phenotype) (NN correlation) (JJ murine) (NN Apc) (NN mutation)) (: :) (NP (NN difference) (NN enterocyte) (NN migration) (NN response) (NN sulindac)))) |ET| |BS|3:C04.557.470.035.215.100 11:B01.050.150.900.649.865.635.505.500 18:G05.365.590 251:D02.455.426.559.847.486.875 1475:A03.556.124.369.290 1476:E05.393.385|ES| 19:1 34:1 104:1 280:1 494:1 514:1 627:1 869:1 1674:1 3544:1 5427:1 5428:1
1 	|BT| (S (NP (NN Hesperidin) (NN treatment)) (VP (VBD caused) (SBAR (S (NP (JJ significant) (NP (NP (NN up-regulation) (NN tumour) (NN suppressor) (NN phosphatase) (NN tensin) (NN homologue)) (PRN (-LRB- -LRB-) (NP (NN PTEN)) (-RRB- -RRB-))) (NN reduction) (NN expression) (NNP AOM)) (VP (VBD mediated) (NP (NN p-PI3K) (NN p-Akt))))))) |ET| |BS|52:E02 132:D02.172.080 142:I01.880.604 206:G05.360.340.024.340.375.249 378:D08.811.913.696.620.682.700.755 1035:D08.811.277.352.650 1290:D08.811.913.696.620.500 1477:D03.383.663.283.266.450.252.500|ES| 10:1 14:1 19:1 115:1 135:1 226:1 370:1 437:1 546:1 700:1 896:1 1011:1 1936:1 1994:1 2506:1 3619:1 3620:1 5429:1 5430:1 5431:1
1 	|BT| (S (NP (NP (ADJP (RB Highly) (JJ metastatic)) (JJ hepatocellular) (NN carcinoma)) (VP (VBD induced) (NP (NP (JJ male) (NN F344) (NN rat)) (NP (VBN treated) (NN N-nitrosomorpholine) (NN combination) (NNS hepatocarcinogens))))) (VP (VBP show) (NP (JJ high) (NN incidence) (NN p53) (NN gene) (NN mutation)) (PP (IN along) (NP (JJ altered) (NN mRNA) (NN expression) (JJ tumor-related) (NN gene))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 8:C04 18:G05.365.590 52:E02 104:C04.557.470.200.025.255 111:D13.444.735.544 149:G05.360.340.024.340.364.875.890 155:G05.355.310 434:E05.318.308.985.525.375 590:B01.050.050.199.520.760.200|ES| 9:1 12:1 19:1 34:1 115:1 178:1 303:1 304:1 325:1 337:1 412:1 429:1 530:1 693:1 849:1 1099:1 1402:1 1511:1 2666:1 2705:1 3185:1 3989:1 5432:1 5433:1
1 	|BT| (NP (NP (NP (NP (NN Histogenesis) (NN role) (NN p53) (NN K-ras) (NN mutation) (NN hepatocarcinogenesis) (NN glyceryl) (NN trinitrate)) (PRN (-LRB- -LRB-) (NP (NN nitroglycerin)) (-RRB- -RRB-))) (JJ male) (NN F344) (NN rat))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550 2:G05.360.340.024.340.375.249.385 15:F01.829.316.616 18:G05.365.590 590:B01.050.050.199.520.760.200 1478:D02.033.800.421.560|ES| 10:1 12:1 14:1 19:1 31:1 34:1 849:1 900:1 1121:1 1402:1 3185:1 5434:1 5435:1 5436:1 5437:1
1 	|BT| (S (PP (IN In) (NP (NN addition))) (, ,) (NP (NN IBN-65)) (VP (VP (VBD induced) (NP (NP (NN apoptosis)) (NP (JJ down-regulating) (NNP Survivin)))) (, ,) (NP (NP (NN Bcl-2) (VBG up-regulating) (NN Bax)) (, ,) (VP (VBG leading) (NP (JJ sequential) (NN activation) (NN Caspase-3))) (, ,) (NP (NP (NN Caspase-9) (NN cleavage) (NN poly) (-LRB- -LRB-) (NN ADP-ribose) (-RRB- -RRB-) (NN polymerase)) (PRN (-LRB- -LRB-) (NP (NN PARP)) (-RRB- -RRB-)))))) |ET| |BS|39:G04.299.139.160 54:G05.360.340.024.340.375.500.791.150 86:D01.268.556.435 150:Z01.542.248.960 342:D12.644.360.075.718.400 351:A17.360 906:D08.811.277.656.262.500.126.350.300 1248:D08.811.913.400.725.115.690 1349:D08.811.277.656.262.500.126.550.900 1440:G04.299.134.220.250|ES| 2:1 10:1 14:1 19:1 89:1 158:1 225:1 244:1 394:1 412:1 468:1 639:1 1876:1 3097:1 3190:1 3779:1 4630:1 4810:1 4811:1 5247:1 5438:1 5439:1 5440:1 5441:1
1 	|BT| (S (PP (IN In) (NP (NN addition))) (, ,) (NP (NN metformin)) (VP (VBD induced) (NP (NP (NN apoptosis) (NN OSCC) (NN cell)) (, ,) (VP (ADVP (RB significantly)) (VBG down-regulating) (NP (NP (JJ anti-apoptotic) (NN protein) (NN Bcl-2) (NN Bcl-xL)) (VP (VBG up-regulating) (NP (JJ pro-apoptotic) (NN protein) (NN Bax)))))))) |ET| |BS|39:G04.299.139.160 41:A11 54:G05.360.340.024.340.375.500.791.150 150:Z01.542.248.960 342:D12.644.360.075.718.400 351:A17.360 784:D02.078.370.141.450 1469:D12.644.360.075|ES| 2:1 4:1 19:1 89:1 94:1 124:1 158:1 244:1 412:1 468:1 1876:1 3097:1 4630:1 4814:1 5087:1 5230:1 5232:1 5442:1
1 	|BT| (S (PP (IN In) (NP (NN HT-29) (NN cell))) (, ,) (NP (NN pterostilbene)) (VP (VBD reduced) (SBAR (S (NP (NP (NN protein) (NN level) (NN beta-catenin)) (, ,) (NP (NN cyclin) (NN D1) (NN c-MYC)) (, ,) (NP (JJ altered) (JJ cellular) (NN localization) (NN beta-catenin))) (VP (VBD inhibited) (NP (NN phosphorylation) (NN p65))))))) |ET| |BS|7:D12.776 23:D12.776.091.249 41:A11 122:C14.280.383 215:D12.644.360.262.150.100 792:A11.251.210.190.475 972:G02.111.087.677|ES| 2:1 4:1 19:1 60:1 94:1 244:1 249:1 365:1 452:1 625:1 693:1 743:1 744:1 2428:1 2484:1 2782:1 3074:1 3426:1 5016:1
1 	|BT| (S (PP (IN In) (NP (NN HT-29) (NN cell))) (, ,) (NP (NN pterostilbene)) (VP (VBD reduced) (SBAR (S (NP (NP (NN protein) (NN level) (NN beta-catenin)) (, ,) (NP (NN cyclin) (NN D1) (NN c-MYC)) (, ,) (NP (JJ altered) (JJ cellular) (NN localization) (NN beta-catenin))) (VP (VBD inhibited) (NP (NN phosphorylation) (NN p65))))))) |ET| |BS|7:D12.776 23:D12.776.091.249 32:C04.697.098.500 33:C04.697.098 41:A11 46:A03.556.124.526.356 122:C14.280.383 158:D23.101 183:G04.299.233.750 215:D12.644.360.262.150.100 792:A11.251.210.190.475 972:G02.111.087.677|ES| 2:1 4:1 18:1 19:1 60:1 78:1 94:1 113:1 159:1 216:1 244:1 249:1 299:1 365:1 378:1 452:1 534:1 625:1 658:1 693:1 743:1 744:1 787:1 793:1 796:1 827:1 1474:1 1659:1 2250:1 2428:1 2430:1 2484:1 2782:1 3074:1 3426:1 5016:1
1 	|BT| (S (PP (IN In) (NP (NN summary))) (, ,) (NP (VBN shown) (JJ first) (NN time) (NN UDCA)) (VP (VBD suppressed) (SBAR (S (NP (NN development) (NN tumor) (NN Ras) (NN mutation)) (VP (VBD blocked) (NP (NN activation) (NNP WT) (NN Ras))))))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550 8:C04 18:G05.365.590 322:G01.910 737:D04.808.105.225.272.962|ES| 2:1 7:1 19:1 34:1 35:1 225:1 237:1 244:1 307:1 490:1 816:1 1081:1 1775:1 1995:1 2631:1 2777:1
1 	|BT| (FRAG (PP (IN In) (NP (NP (NNP AOM)) (ADVP (RB alone)))) (NP (NP (NN group)) (, ,) (NP (NN Cox-2)) (VP (VBD up-regulated) (SBAR (S (NP (ADJP (JJR >) (JJ 50-fold)) (NN tumor) (JJ normal) (NP (NN Ras)) (NN activity)) (VP (VBD enhanced) (NP (NN tumor) (JJ mutant) (JJ signaling-activated) (NN Ras)))))))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550 8:C04 69:G02.111.087.800 132:D02.172.080 142:I01.880.604 150:Z01.542.248.960 829:M01.686|ES| 2:1 7:1 19:1 62:1 118:1 241:1 244:1 385:1 399:1 811:1 1301:1 1466:1 1775:1 1994:1 2300:1 5443:1 5444:1
1 	|BT| (FRAG (PP (IN In) (NP (NN study))) (, ,) (NP (VBN examined) (NN role) (NN Ras) (NN Cox-2) (NN inhibition) (NN UDCA))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550 15:F01.829.316.616 43:F01.145.544 737:D04.808.105.225.272.962|ES| 2:1 19:1 31:1 62:1 103:1 131:1 244:1 324:1 1775:1 2631:1
1 	|BT| (S (NP (NN Induction) (NN apoptosis) (NN pectenotoxin-2)) (VP (VBD mediated) (NP (NP (NP (NN induction) (NN DR4/DR5)) (, ,) (NP (NN Egr-1) (NN NAG-1))) (, ,) (NP (NN activation) (NN caspase) (NN modulation) (NN Bcl-2) (NN family) (JJ p53-deficient) (NN Hep3B) (JJ hepatocellular) (NN carcinoma) (NN cell))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 39:G04.299.139.160 41:A11 44:F01.829.263 54:G05.360.340.024.340.375.500.791.150 104:C04.557.470.200.025.255 580:D12.776.260.158.500 1367:D08.811.277.656.262.500.126|ES| 2:1 19:1 89:1 94:1 97:1 158:1 225:1 303:1 304:1 437:1 736:1 1662:1 1945:1 2020:1 4498:1 4502:1 4561:1 4796:1 5236:1 5445:1
1 	|BT| (S (NP (NN Induction) (NN SPARC)) (VP (VBD demonstrated) (NP (NN treatment) (JJ demethylating) (NN agent) (NN 5Aza-dC) (CD 5) (CD 7) (NN cell) (NN line)))) |ET| |BS|37:D12.776.157.125.715 94:A11.251.210 775:E02.760.058|ES| 19:1 82:1 94:1 264:1 546:1 578:1 728:1 988:1 1175:1 2020:1 5446:1 5447:1
1 	|BT| (S (NP (NN IR-5) (NN bear) (JJ novel) (NN point) (NN mutation) (NN HER2/neu)) (VP (VP (VBZ corresponds) (SBAR (S (NP (NN L726I) (JJ ATP-binding) (NN pocket)) (VP (VBP correlate) (NP (NN log) (NN decrease) (NN sensitivity) (NN gefitinib)))))) (, ,) (NP (NP (VBD increased) (NN heterodimerization) (NN EGFR) (NN HER3)) (, ,) (NP (JJ impaired) (NN down-regulation))))) |ET| |BS|63:G05.360.340.024.340.375.500.791.295.305 85:G02.111.087.225 259:D12.776.395.240.150.500 438:G05.365.590.675 455:B01.050.150.900.649.147.890 1064:Z01.252.245.500.350 1065:D01.268.556.401|ES| 2:1 19:1 34:1 47:1 187:1 257:1 295:1 607:1 891:1 901:1 1740:1 2003:1 2121:1 3310:1 3505:1 4281:1 4955:1 4956:1 4957:1 4958:1 4959:1 4960:1 4961:1
1 	|BT| (S (S (S (NP (NN Levamisole)) (VP (VBD increased) (NP (NNS ECs) (JJ integrin-dependent) (NN matrix) (NN adhesion)))) (PRN (, ,) (VP (VBD inhibited) (NP (NP (NP (NP (NN proliferation)) (PRN (-LRB- -LRB-) (NP (CD -70) (NN %)) (-RRB- -RRB-))) (, ,) (NP (NP (VBN reduced) (NN expression) (NN survival) (NN factor) (NN clusterin)) (PRN (-LRB- -LRB-) (NP (CD -30) (NN %)) (-RRB- -RRB-))) (, ,) (NP (NN endothelin-1) (PRN (-LRB- -LRB-) (NP (CD -43) (NN %)) (-RRB- -RRB-)))) (, ,) (NP (NN bcl-2) (PRN (-LRB- -LRB-) (NP (CD -34) (NN %)) (-RRB- -RRB-))) (, ,) (NP (NP (JJ endothelial) (NN NO-synthase)) (PRN (-LRB- -LRB-) (NP (CD -32) (NN %)) (-RRB- -RRB-))) (NP (NN pRb) (-LRB- -LRB-) (NN Retinoblastoma) (NN protein) (: :))) (NP (CD -89) (NN %))) (-RRB- -RRB-) (, ,)) (NP (NP (NP (NP (VBN increased) (NN growth) (NN arrest/death) (NN signal) (NN p21)) (PRN (-LRB- -LRB-) (NP (CD +73) (NN %)) (-RRB- -RRB-))) (NN bak)) (PRN (-LRB- -LRB-) (NP (CD +50) (NN %)) (-RRB- -RRB-))))) |ET| |BS|45:G07.700.320.249 54:G05.360.340.024.340.375.500.791.150 96:I03.784 122:C14.280.383 135:C23.550.260 871:D02.886.675.346 920:D12.776.543.750.705.408 1479:D12.776.260.704 1480:D08.811.682.664.500.772.750 1481:D12.644.276.400.225 1482:C23.550.355.274.840 1483:D12.776.395.207 1484:F04.570.200.583|ES| 2:1 4:1 10:1 14:1 19:1 47:1 102:1 104:1 115:1 151:1 185:1 274:1 299:1 365:1 369:1 452:1 753:1 859:1 1135:1 3088:1 3092:1 3093:1 3491:1 5448:1 5449:1 5450:1 5451:1 5452:1 5453:1 5454:1 5455:1 5456:1 5457:1 5458:1 5459:1 5460:1 5461:1 5462:1 5463:1
1 	|BT| (S (NP (JJ Long-term) (JJ pharmacological) (NN MAP) (NN kinase) (NN inhibition) (NN MEK) (NN inhibitor) (NN PD98059)) (VP (VBD induced) (NP (NP (NN expression) (JJ terminal) (NN differentiation) (NN marker) (NN ITF)) (, ,) (NP (NN sucrase-isomaltase)) (, ,) (NP (NN mucin) (NN gene) (NN MUC2))))) |ET| |BS|6:G05.360.340.024.340 43:F01.145.544 71:D12.776.395.560.631 233:D08.811.913.696.620.682.700.565 234:D08.811.913.696.620.682.700.565 478:D08.811.913.696.620.682.700.567 849:G08.686.785.760.769.490.500 1045:D23.050.301.264 1059:H01.158.703 1485:D08.811.277.450.770 1486:V01.185.687|ES| 2:1 9:1 19:1 103:1 115:1 209:1 212:1 215:1 380:1 412:1 470:1 534:1 3707:1 4968:1 5110:1 5464:1 5465:1 5466:1 5467:1 5468:1
1 	|BT| (S (NP (NNS METHODS) (: :)) (PP (IN In) (NP (NN study))) (VP (VBD used) (NP (NP (NN p53)) (VP (VBN mutated) (VP (VB knock) (S (NP (NP (NN colon) (NN cancer) (NN cell) (NN xenograft) (NN tumour) (NN study)) (NN role) (NN p53) (NN apoptosis)) (VP (VBD mediated) (NP (NNS diaminothiazoles))))))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 8:C04 15:F01.829.316.616 30:Z01.058.290.190.800 31:D08.811.520.224.800 39:G04.299.139.160 41:A11 92:E04.936.764 93:A01.941.875 168:E05.581|ES| 12:1 18:1 19:1 31:1 89:1 94:1 104:1 113:1 131:1 229:1 244:1 265:1 437:1 476:1 565:1 1011:1 5469:1 5470:1
1 	|BT| (S (NP (NN MicroRNA-122)) (VP (VBZ inhibits) (SBAR (S (NP (JJ tumorigenic) (NN property) (JJ hepatocellular) (NN carcinoma) (NN cell)) (VP (VBZ sensitizes) (NP (NN cell) (NN sorafenib))))))) |ET| |BS|41:A11 104:C04.557.470.200.025.255 122:C14.280.383 184:D13.150.650.319 575:V02.050|ES| 19:1 94:1 303:1 304:1 615:1 841:1 1797:1 1809:1 2062:1 2063:1
1 	|BT| (S (ADVP (RB Moreover)) (, ,) (NP (NN inhibition) (NN autophagy) (NN sensitization) (NN cisplatin) (NN NAC1) (NN knockdown) (NN inactivation)) (VP (VBN accompanied) (NP (NN induction) (NN apoptosis)))) |ET| |BS|39:G04.299.139.160 43:F01.145.544 390:G04.299.139.399 498:D01.210.375|ES| 2:1 19:1 89:1 103:1 464:1 622:1 736:1 1314:1 1317:1 1761:1 2137:1 2801:1 5471:1
1 	|BT| (NP (NP (NP (NN Mutation) (NN analysis) (NN XPA)) (PRN (-LRB- -LRB-) (: -) (: /) (: -) (-RRB- -RRB-))) (NP (NP (NN mouse) (VBG carrying) (NN lacZ) (NN reporter) (NN gene)) (, ,) (S (VP (VBD indicated) (SBAR (S (NP (VBN observed) (NN toxicity) (NN PhIP)) (VP (MD might) (VP (VBD caused) (NP (JJ genotoxic) (NN effect) (JJ small) (NN intestine)))))))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 18:G05.365.590 100:G05.360.340.024.686.545 218:A03.556.124.684 247:G01.374.676.530|ES| 2:1 9:1 10:1 14:1 19:1 45:1 52:1 75:1 261:1 288:1 356:1 641:1 661:1 750:1 798:1 850:1 1541:1 2406:1 2506:1 2641:1 3329:1 5416:1 5472:1
1 	|BT| (S (NNS Mutations) (NP (NN codon) (NP (CD 13) (CD 117) (CC plus) (NP (JJ second) (NN exon) (NN insert)))) (VP (VBD contributed) (NP (CD 4) (NN %)) (NP (JJ total) (JJ H-ras) (NN frequency) (NN trichloroethylene) (NN tetrachloroethylene)))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550 18:G05.365.590 113:C04.697.650 179:D01.248.497.300.459.700 335:D13.444.735.544.355 372:G05.360.340.024.340.137.232 1235:D02.455.526.439.939 1236:D02.455.526.439.880|ES| 19:1 319:1 369:1 1119:1 1247:1 1255:1 1410:1 1532:1 2347:1 3132:1 4416:1 4888:1 5473:1 5474:1 5475:1 5476:1 5477:1
1 	|BT| (S (NP (NNP Nestin) (NN silencing)) (VP (ADVP (RB also)) (VP (VBD upregulated) (NP (NP (NN Axin) (, ,) (NP (NP (NN glycogen) (NN synthase) (NN kinase-3) (NN beta)) (PRN (-LRB- -LRB-) (NP (NN GSK-3beta)) (-RRB- -RRB-))) (, ,) (NP (JJ adenomatous) (NN polyposis) (NN coli) (PRN (-LRB- -LRB-) (NP (NN APC)) (-RRB- -RRB-))) (, ,)) (NP (NP (NN peroxisome) (JJ proliferator-activated) (NN receptor) (NN alpha)) (PRN (-LRB- -LRB-) (NP (NN PPARa)) (-RRB- -RRB-))))) (, ,) (VP (VBD downregulated) (NP (NP (NN beta-catenin)) (, ,) (NP (NN c-Myc)) (, ,) (NP (NP (NN cyclin) (NN D)) (NN MMP-7) (NN expression) (NNP CSC)))))) |ET| |BS|3:C04.557.470.035.215.100 21:G05.360.340.024.340.375.249.050 23:D12.776.091.249 536:D12.776.826.239.500 556:C11.768.175 937:D08.811.277.656.300.480.525.700.250 1046:D12.644.360.262.150 1047:D05.750.078.593.540|ES| 2:1 5:1 10:1 11:1 14:1 19:1 57:1 58:1 59:1 60:1 66:1 92:1 100:1 115:1 125:1 186:1 426:1 743:1 824:1 1801:1 1836:1 1887:1 1972:1 2592:1 3577:1 3650:1 3651:1 3652:1 3653:1 3654:1 3655:1
1 	|BT| (S (ADVP (RB Notably)) (, ,) (NP (NN AcEGCG)) (VP (VP (VBD inhibited) (NP (NP (NN expression) (NN p53) (, ,) (NN p21) (, ,) (NN c-Myc) (, ,) (NN cyclin) (NN B)) (, ,) (NP (NN p-CDK1) (NN Cdc25A))) (ADVP (RB also)) (VP (VBD restored) (NP (NN activation) (NP (NP (JJ extracellular) (JJ signal-regulated) (NN kinase) (CD 1/2)) (PRN (-LRB- -LRB-) (NP (NN ERK1/2)) (-RRB- -RRB-)))))) (, ,) (VP (VBD decreased) (NP (JJ DMBA/TPA-induced) (NN increase) (NN tumor) (NN proliferation) (JJ mitotic) (NN index))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 8:C04 116:D08.811.913.696.620.682.700.567.249.750 122:C14.280.383 212:E01.370.225.500.385.500 1487:D08.811.913.696.620.682.700.646.500.500.250 1488:D02.455.426.559.847.149.301 1489:D08.811.277.656.300.760.875 1490:D12.644.360.262.120|ES| 2:1 5:1 7:1 10:1 12:1 14:1 19:1 40:1 115:1 202:1 225:1 299:1 365:1 470:1 720:1 721:1 743:1 763:1 824:1 1135:1 1707:1 2798:1 4594:1 4812:1 4893:1 4966:1 5478:1 5479:1 5480:1 5481:1
1 	|BT| (S (NP (NN OBJECTIVE) (: :)) (NP (NN FBXW7)) (VP (VBZ encodes) (NP (SBAR (S (NP (JJ substrate) (NN recognition) (NN component) (NN ubiquitin) (NN ligase)) (VP (VBZ degrades) (NP (NN target) (NN Notch1))))) (, ,) (NP (NN c-Jun)) (, ,) (NP (NN c-Myc) (NN cyclin) (NN E))))) |ET| |BS|415:F01.658.500 1458:D12.644.360.262.180 1491:F02.463.425.540.706 1492:D12.776.947.500 1493:D08.811.464|ES| 2:1 19:1 104:1 160:1 651:1 743:1 824:1 1021:1 1417:1 1686:1 2085:1 2211:1 3470:1 3757:1 5127:1 5482:1 5483:1 5484:1
1 	|BT| (S (SBAR (IN Of) (S (NP (CD two) (NN gene)) (VP (VBP encode) (NP (NP (NN methionine) (NN adenosyltransferase)) (PRN (-LRB- -LRB-) (NP (NN MAT1Aand) (NN MAT2A)) (-RRB- -RRB-)))))) (, ,) (NP (NN MAT1A)) (ADVP (RB mainly)) (VP (VBD expressed) (NP (JJ adult) (NN liver)) (SBAR (IN whereas) (S (NP (NN MAT2A)) (VP (VBD expressed) (NP (JJ extrahepatic) (NN tissue))))))) |ET| |BS|6:G05.360.340.024.340 98:A10 119:M01.060.116 242:A03.620 574:D08.811.913.225.650|ES| 2:1 6:1 9:1 10:1 14:1 19:1 272:1 355:1 372:1 836:1 933:1 1429:1 1792:1 2050:1 2051:1 5485:1 5486:1 5487:1 5488:1 5489:1
1 	|BT| (S (NP (RB Only) (NN 10-MeBaA)) (VP (VBD induced) (S (NP (NP (NN apoptosis) (NN accumulation)) (VP (VBN phosphorylated) (S (NP (NN p53))))) (, ,) (VP (MD could) (NP (NP (VBN associated) (NN induction) (JJ oxidative) (NN stress)) (, ,) (NP (JJ similar) (NN DMBA))))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 39:G04.299.139.160 716:G03.495.710 1488:D02.455.426.559.847.149.301|ES| 2:1 12:1 19:1 89:1 169:1 332:1 412:1 736:1 908:1 2120:1 2522:1 2583:1 4930:1 5490:1 5491:1 5492:1
1 	|BT| (S (NP (PRP$ Our) (NN model)) (VP (VBZ predicts) (NP (NP (NP (NN 5FU) (NN sensitivity) (NN tumor)) (VP (VBN modified) (S (NP (NN aneuploidy)) (VP (VBG producing) (NP (NN copy) (NN number) (NN change) (NN TS) (NN allele) (CD one) (NN following)))))) (: :) (NP (NP (NN LOH)) (, ,) (NP (NN amplification)) (, ,) (, ,) (NP (VBN presented) (, ,) (NP (NN copy) (NN number) (NN change) (JJ due) (NN polysomy))))))) |ET| |BS|8:C04 77:G05.360.340.024.340.030 154:Z01.058.266.887 290:G05.365.590.029.530 560:D03.383.742.698.875.404 1494:C23.550.210.050|ES| 2:1 7:1 19:1 72:1 104:1 200:1 230:1 509:1 607:1 646:1 658:1 921:1 963:1 1004:1 1010:1 1751:1 2335:1 2851:1 3510:1 5493:1 5494:1 5495:1 5496:1 5497:1
1 	|BT| (S (NP (PRP$ Our) (NN study)) (ADVP (RB also)) (VP (VBP demonstrate) (NP (VBN utilized) (NN DEN/PB) (NN protocol) (NNP WT) (NN C57BL/6) (NN mouse) (JJ select) (NN beta-catenin) (NN gene) (NN mutation) (NN hepatocarcinogenesis)))) |ET| |BS|18:G05.365.590 23:D12.776.091.249 593:B01.050.050.199.520.520.420|ES| 5:1 9:1 19:1 34:1 52:1 60:1 131:1 502:1 658:1 900:1 1182:1 1995:1 2192:1 3216:1 4183:1 5498:1
1 	|BT| (S (NP (NN Panobinostat) (NN treatment)) (VP (VBD induced) (NP (NP (NP (NN downregulation) (NN EGFR)) (, ,) (NP (NN HER2)) (, ,)) (NN HER3) (ADJP (NN mRNA) (NN protein) (JJ transcriptional) (JJ posttranslational)) (NN mechanism)))) |ET| |BS|7:D12.776 52:E02 63:G05.360.340.024.340.375.500.791.295.305 65:D08.811.913.696.620.682.725.400.009.400 85:G02.111.087.225 111:D13.444.735.544 209:G02.111.087.847|ES| 2:1 4:1 19:1 162:1 187:1 188:1 325:1 412:1 546:1 559:1 595:1 4961:1 5499:1 5500:1
1 	|BT| (FRAG (NP (NP (NP (NN PhIP) (NN diet)) (NP (ADJP (JJR >) (ADJP (CD 43) (NN week))) (NP (JJ present) (NN colon) (NN tumor) (JJ specific) (CD -1) (NN G) (NN mutation)))) (PP (IN within) (NP (QP (CD 5) ('' ')) (: -) (NN GGGA-3) ('' ') (NN sequence) (NN APC))) (: :)) (NP (NN gene))) |ET| |BS|3:C04.557.470.035.215.100 6:G05.360.340.024.340 18:G05.365.590 26:G02.111.570.080 51:C04.588.274.476.411.307.180 595:G07.203.650.240 596:E02.642.249|ES| 7:1 9:1 11:1 19:1 34:1 104:1 113:1 293:1 540:1 783:1 1307:1 1466:1 1489:1 2122:1 2191:1 2641:1 5501:1 5502:1 5503:1
-1 	|BT| (NP (NP (NN OBJECTIVE)) (: :) (NP (NP (PRP We)) (VP (VBD aimed) (NP (NN test) (IN whether) (NP (NP (NN association) (JJ colorectal) (NN polyp) (NN intake) (NN calcium)) (, ,) (NP (NN magnesium)) (, ,) (NP (NP (NN Thr1482Ile) (NN polymorphism) (NN TRPM7) (NN gene)) (VP (VBN modified) (NP (NN Ca)))) (: :)) (NN Mg) (NN intake))))) |ET| |BS|6:G05.360.340.024.340 30:Z01.058.290.190.800 31:D08.811.520.224.800 307:G05.365.795 386:F02.463.425.069 415:F01.658.500 444:C23.300.825 1026:Z01.252.474.651 1507:A08.186.211.464.405 1508:D01.268.552.437 1509:D01.268.552.100 1510:D01.146.315|ES| 2:1 9:1 17:1 19:1 104:1 221:1 647:1 843:1 844:1 1060:1 1298:1 1417:1 1418:1 2335:1 2563:1 5564:1 5565:1 5566:1 5567:1 5568:1 5569:1
-1 	|BT| (S (ADVP (RB Altogether)) (, ,) (VP (VBP result) (SBAR (S (NP (NN show) (NN identification) (JJ BET-dependent) (NN gene)) (VP (VBZ provides) (NP (NN guidance) (NN choice) (NN drug) (NN combination) (NN cancer) (NN treatment))))))) |ET| |BS|6:G05.360.340.024.340 52:E02 374:F01.393.446 1511:F02.463.785.373.346 1512:F01.145.722.408 1513:D26.310|ES| 2:1 9:1 18:1 19:1 101:1 191:1 429:1 530:1 546:1 815:1 3469:1 5570:1 5571:1 5572:1 5573:1
-1 	|BT| (S (NP (NNS Analyses) (NN xenograft)) (VP (VBD showed) (SBAR (S (NP (NP (JJ similar) (NN cell) (NN culture) (NN finding)) (, ,) (NP (NN silibinin) (NN decrease) (NN proliferation) (NN expression) (NN beta-catenin)) (, ,) (NP (NN cyclin) (NN D1)) (, ,) (NP (NP (NN c-Myc)) (, ,) (NP (NN CDK8)))) (VP (VBZ induces) (NP (NN apoptosis)) (ADVP (FW vivo))))))) |ET| |BS|23:D12.776.091.249 39:G04.299.139.160 92:E04.936.764 93:A01.941.875 215:D12.644.360.262.150.100 1514:E01.370.225.500.223|ES| 2:1 19:1 60:1 89:1 94:1 115:1 132:1 214:1 265:1 295:1 299:1 332:1 378:1 743:1 744:1 824:1 927:1 2635:1 3098:1 5574:1 5575:1
-1 	|BT| (FRAG (PP (IN Because) (NP (NP (NN combination) (JJ anti-EGFR) (NN 5-fluorouracil) (-LRB- -LRB-) (NP (NN 5-FU) (-RRB- -RRB-) (: -)) (VP (VBN based) (NP (NN chemotherapy) (JJ promising) (NN treatment)))) (, ,) (SBAR (S (NP (VBN analyzed) (NN effect) (NN K-Ras) (NN mutation) (NN patient)) (VP (VBD received) (NP (JJ exclusive) (NN 5-FU) (NN therapy)))))))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550 18:G05.365.590 50:M01.643 52:E02 151:E02.319 333:D01.045 560:D03.383.742.698.875.404|ES| 2:1 10:1 13:1 14:1 19:1 34:1 75:1 120:1 130:1 495:1 530:1 546:1 549:1 1168:1 1517:1 1862:1 2307:1 2308:1 2895:1 4339:1 5576:1
-1 	|BT| (S (S (NP (DT Both) (NNP Tyr) (-LRB- -LRB-) (CD 705) (-RRB- -RRB-) (NN phosphorylation) (NN binding) (NN STAT3) (NN MICA) (NN promoter)) (VP (VBD reduced) (NP (NN GSK3) (NN inhibitor)))) (: ;) (S (NP (NP (NN addition)) (, ,) (NP (NP (NN overexpression)) (NP (ADJP (RB constitutively) (JJ active)) (NN form) (NN STAT3)))) (ADVP (RB significantly)) (VP (VBZ inhibits) (NP (NNP MICA) (NN upregulation))))) |ET| |BS|82:D12.644.360.024.342.300 122:C14.280.383 189:V02.460 249:G05.355.315.800 339:G02.111.087.880 519:D05.500.117.875 634:D12.125.072.050.875 972:G02.111.087.677 1206:D08.811.682.690.708.125.500|ES| 2:1 10:1 14:1 19:1 83:1 124:1 152:1 196:1 197:1 217:1 251:1 380:1 452:1 468:1 615:1 630:1 1126:1 1487:1 3426:1 4232:1 4678:1 5577:1 5578:1 5579:1
-1 	|BT| (SINV (PP (IN By) (NP (NN sequencing) (NN Apc) (NN Ctnnb1) (NN gene))) (, ,) (VBD found) (S (S (NP (JJ PhIP-induced) (JJ small) (JJ intestinal) (NN tumor) (JJ obese) (NN mouse)) (VP (VBD carried) (NP (JJ single) (JJ heterozygous) (NN mutation) (NN Apc)) (PP (IN By) (NP (JJ bisulfite-sequencing) (NN CpG) (NN island) (NN Apc))))) (, ,) (VP (VBD found) (NP (NP (NN DNA) (NN hypermethylation) (NN CpG) (NN cluster) (JJ located) (NN transcription) (NN initiation) (NN site)) (, ,) (SBAR (S (ADVP (JJ likely)) (VP (VBD caused) (NP (NN inactivation) (JJ wild-type) (NN Apc) (NN allele))))))))) |ET| |BS|3:C04.557.470.035.215.100 6:G05.360.340.024.340 8:C04 18:G05.365.590 23:D12.776.091.249 25:G02.111.570.080 26:G02.111.570.080 27:G02.111.570.080 38:Z01.058.290.120.180 40:Z01.542.248.700 77:G05.360.340.024.340.030 157:G05.380.383 195:G02.111.570.080.380.160 198:D13.444.308 218:A03.556.124.684 247:G01.374.676.530 765:B01.050.150.900.649.865.635.505.500.550.530 805:F01.829.263.315.500.725 806:F01.829.263.315.500.725 1515:G05.360.340.024.340.137.750.840 1516:G02.111.570.080.380.160|ES| 2:1 7:1 8:1 9:1 19:1 34:1 37:1 52:1 109:1 230:1 280:1 487:1 637:1 662:1 663:1 664:1 666:1 750:1 786:1 1003:1 1314:1 1328:1 1839:1 1868:1 2205:1 2468:1 2506:1 2846:1 4032:1 4435:1 5580:1 5581:1 5582:1
-1 	|BT| (S (NNS Changes) (NP (JJ circadian) (NN cycle) (NN gene)) (: -) (S (NP (RB primarily) (NP (NN transcription) (NN factor)) (: -)) (VP (VBD showed) (SBAR (S (NP (ADJP (NP (JJ strong) (JJ concentration-related) (NN response)) (JJR higher)) (NN concentration)) (-LRB- -LRB-) (S (NP (NP (NN Arntl)) (, ,) (NP (NN Npas2)) (, ,) (NP (NN Clock))) (VP (VBD down-regulated))) (: ;) (PRN (NP (NP (NN Cry2)) (, ,) (NP (NN Wee1)) (, ,) (NP (NN Bhlhe40)) (, ,) (NP (NN Per3)) (, ,) (NP (NN Nr1d1)) (, ,) (NP (NN Nr1d2) (NN Dbp))) (-RRB- -RRB-) (S (VP (VBD up-regulated) (NP (JJ similar) (NN directionality) (NN tissue)))))))))) |ET| |BS|98:A10 142:I01.880.604 150:Z01.542.248.960 166:D12.776.930 351:A17.360 776:G01.910.645 905:F02.830.104.214|ES| 2:1 9:1 10:1 14:1 19:1 132:1 170:1 185:1 217:1 272:1 332:1 487:1 494:1 601:1 1283:1 1301:1 1970:1 2691:1 3189:1 3578:1 5337:1 5583:1 5584:1 5585:1 5586:1 5587:1 5588:1 5589:1 5590:1 5591:1 5592:1 5593:1 5594:1 5595:1
-1 	|BT| (S (NP (JJ Chemopreventive) (NN activity) (NN plant) (NN flavonoid) (NN isorhamnetin) (JJ colorectal) (NN cancer)) (VP (VBN mediated) (NP (JJ oncogenic) (NN Src) (NN beta-catenin)))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 23:D12.776.091.249 279:D27.888.569.100 328:B01.650 534:D03.383.663.283.266.450|ES| 17:1 18:1 19:1 60:1 399:1 437:1 953:1 1098:1 1886:1 3673:1 3674:1 3972:1
-1 	|BT| (S (ADVP (RB Collectively)) (, ,) (VP (VBP result) (VP (VBP suggest) (SBAR (S (NP (JJ potential) (JJ novel) (JJ epigenetic) (NN mechanism)) (VP (VBZ underlies) (SBAR (S (NP (NP (JJ chemopreventive) (NN effect) (NN ASA)) (, ,) (NP (NN mechanism)) (VP (VBZ attenuates) (NP (NNP CAC) (JJ AOM/DSS-induced) (NN CF-1) (NN mouse)) (PP (IN via) (NP (NN inhibition) (NNS HDACs) (NN modification) (NN H3K27ac) (NN mark))))) (VP (VBP suppress) (NP (NP (NN iNOS)) (, ,) (NP (NN TNF-alpha)) (NP (NN IL-6)))))))))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 43:F01.145.544 132:D02.172.080 201:D12.644.276.374.465.224 259:D12.776.395.240.150.500 624:D27.505.696.706.018 670:D02.455.426.559.389.657.410.595.176 671:G05.355.315.203 789:D12.644.276.374.500.800 790:D12.644.276.374.750 1008:D08.811.277.087.520 1114:D08.811.277.352.827.070.250|ES| 2:1 19:1 52:1 67:1 75:1 101:1 103:1 162:1 596:1 796:1 827:1 891:1 1603:1 1872:1 1946:1 2374:1 2423:1 2441:1 2451:1 2775:1 3066:1 3148:1 4755:1 5596:1 5597:1 5598:1 5599:1 5600:1
-1 	|BT| (S (ADVP (RB Consistently)) (, ,) (VP (VBD found) (SBAR (S (NP (NN simvastatin)) (ADVP (RB also)) (VP (VBD increased) (NP (NP (NN p21) (NN p27) (NN expression) (NN tumor) (NN section)) (VP (VBG reducing) (NP (NP (NN Skp2) (NN expression)) (VP (VBG inducing) (NP (NN AMPK) (NN activation) (NN STAT3) (NN suppression) (NN tumor) (NN tissue))))))))))) |ET| |BS|8:C04 82:D12.644.360.024.342.300 98:A10 507:D12.776.157.743 754:D02.455.426.559.847.638.400.900|ES| 2:1 5:1 7:1 19:1 37:1 47:1 115:1 225:1 251:1 272:1 1124:1 1135:1 1785:1 1864:1 2453:1 2679:1 3331:1 4686:1 4691:1 4692:1
-1 	|BT| (S (NP (NN CpG) (NN island) (NN methylation) (NN expression) (NN ALX4)) (VP (VP (VBD evaluated) (NP (NP (JJ methylation-specific) (NN polymerase) (NN chain) (NN reaction)) (PRN (-LRB- -LRB-) (NP (NN PCR)) (-RRB- -RRB-)))) (, ,) (NP (NP (JJ bisulfite) (JJ genomic) (NN sequencing)) (, ,) (NP (JJ reverse-transcription) (NN PCR) (NN Western) (NN blotting))))) |ET| |BS|36:G02.111.087.029.538 195:G02.111.570.080.380.160 225:E05.337 256:E05.196.401.143 268:H01.158.273.180.350 269:G05.360.340 272:E05.393.620.500.725 448:E05.393.620.500|ES| 2:1 10:1 14:1 19:1 81:1 115:1 394:1 662:1 663:1 768:1 780:1 872:1 875:1 910:1 941:1 4584:1 5580:1 5601:1 5602:1 5603:1 5604:1
-1 	|BT| (S (NP (NN Demethylation) (NN experiment)) (VP (VBD confirmed) (NP (NP (NN loss) (NN ALX4) (NN expression)) (VP (VBN regulated) (NP (NN CpG) (NN island) (NN hypermethylation)))))) |ET| |BS|142:I01.880.604 195:G02.111.570.080.380.160|ES| 19:1 32:1 115:1 662:1 663:1 664:1 938:1 1664:1 2632:1 5601:1 5605:1
-1 	|BT| (S (NP (JJ DEN-induced) (NN rat)) (VP (VBD exhibited) (NP (NP (VBN increased) (NN gene) (NN expression) (NN NF-kappaB)) (, ,) (NP (NN COX-2)) (, ,) (NP (NN CYP2E1)) (, ,) (NP (NN VEGF)) (, ,) (NP (NN Bcl-2)) (, ,) (NP (NN PI3K/AKT/mTOR))) (S (ADVP (RB significantly)) (VP (VBD decreased) (NP (NP (NN gene) (NN expression) (NN p53)) (, ,) (NP (NN Bax)) (, ,) (NP (NN caspase-9) (NN caspase-3))))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 54:G05.360.340.024.340.375.500.791.150 155:G05.355.310 175:J01.897.280.500.269 210:D12.776.260.600 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 342:D12.644.360.075.718.400 378:D08.811.913.696.620.682.700.755 906:D08.811.277.656.262.500.126.350.300 1218:D08.244.453.300 1290:D08.811.913.696.620.500 1349:D08.811.277.656.262.500.126.550.900|ES| 2:1 9:1 12:1 19:1 47:1 76:1 115:1 124:1 158:1 202:1 609:1 714:1 849:1 2066:1 2735:1 4270:1 4630:1 4807:1 4808:1 5606:1
-1 	|BT| (NP (NP (NP (NN Dependence) (NNS diaminothiazoles)) (, ,) (NP (NN compound)) (VP (VBD gained) (NP (NP (NP (NP (NN importance)) (ADJP (RB recently) (JJ due))) (JJ anticancer) (JJ anti) (JJ angiogenic) (NN activity)) (, ,) (NP (NP (VBN tested) (NN cancer) (NN model)) (VP (VBG varying) (NP (NN p53) (NN Ras/Raf) (JJ mutational) (NN status)))))))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550 2:G05.360.340.024.340.375.249.385 18:G05.365.590 1517:F01.752.330|ES| 2:1 12:1 18:1 19:1 72:1 399:1 416:1 772:1 1244:1 1660:1 1880:1 2433:1 2851:1 2988:1 3790:1 5470:1 5607:1 5608:1 5609:1 5610:1 5611:1
-1 	|BT| (FRAG (NP (NP (NP (NP (RB Early) (NN detection)) (JJ 2-amino-1-methyl-6-phenylimidazo) (-LRB- -LRB-) (JJ 4,5-b) (-RRB- -RRB-) (NN pyridine) (-LRB- -LRB-) (NN PhIP) (-RRB- -RRB-) (: -)) (VBN induced) (NN mutation)) (PP (IN within) (NP (NN Apc) (NN gene) (NN rat) (NN colon))))) |ET| |BS|18:G05.365.590 21:G05.360.340.024.340.375.249.050 46:A03.556.124.526.356 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 494:E01.390 744:D03.383.725|ES| 9:1 10:1 14:1 19:1 34:1 113:1 280:1 409:1 849:1 1023:1 2122:1 2638:1 2639:1 2640:1 2641:1 4135:1
-1 	|BT| (S (NP (NNP Emodin)) (ADVP (RB also)) (VP (VBD inhibited) (NP (NP (NN growth) (NN lung) (NN xenograft) (NN tumor) (NN Sp1)) (, ,) (NP (VBD increased) (NN IGFBP1) (NN PPARgamma) (NN protein) (NN expression)) (ADVP (FW In) (FW vivo))))) |ET| |BS|7:D12.776 45:G07.700.320.249 92:E04.936.764 93:A01.941.875 122:C14.280.383 237:C04.588.894.797.520 719:D12.776.826.239.588 1327:D12.776.157.420.250 1518:D02.455.426.559.847.117.159.205.400|ES| 2:1 4:1 5:1 7:1 19:1 47:1 102:1 115:1 244:1 265:1 328:1 365:1 378:1 2588:1 4856:1 5612:1 5613:1
-1 	|BT| (S (NP (JJ Enzymatic) (NN assay)) (VP (VBD showed) (SBAR (S (NP (NN genistein) (NN 5Aza-C) (VBD decreased) (NN DNA) (NN Methyltransferase) (, ,) (JJ methyl-CpG-binding) (NN domain) (CD 2) (NN activity)) (VP (VBD increased) (NP (NN HAT) (NN activity))))))) |ET| |BS|746:D08.811.150.240 944:D03.383.663.283.266.450.400.375 1519:E05.196.427|ES| 2:1 19:1 47:1 132:1 148:1 202:1 310:1 399:1 666:1 1173:1 3314:1 4828:1 5614:1 5615:1 5616:1 5617:1
-1 	|BT| (S (S (NP (NN ERK)) (VP (VBD mediated) (SBAR (S (NP (NN upregulation) (NN death) (NN receptor) (CD 5)) (VP (VBZ overcomes) (SBAR (S (NP (NN lack) (NN p53) (NN functionality) (NN diaminothiazole) (NN DAT1)) (VP (VBD induced) (NP (NN apoptosis) (NN colon) (NN cancer) (NN model)))))))))) (: :) (S (NP (NN efficiency) (NN DAT1) (NN Ras-Raf)) (NP (VBN mutated) (NN cell)))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550 2:G05.360.340.024.340.375.249.385 39:G04.299.139.160 41:A11 249:G05.355.315.800 252:F02.784.692.351 339:G02.111.087.880|ES| 12:1 18:1 19:1 72:1 89:1 94:1 104:1 113:1 186:1 229:1 411:1 412:1 437:1 578:1 868:1 1126:1 3239:1 3910:1 3915:1 3937:1 5047:1 5618:1 5619:1
-1 	|BT| (S (NP (NN Evodiamine)) (ADVP (RB also)) (VP (VBD suppressed) (SBAR (S (NP (NN STAT3) (NN DNA) (NN binding) (NN activity)) (VP (VBD down-regulated) (NP (NP (NN expression) (JJ STAT3-mediated) (NN gene)) (VP (VBG leading) (NP (NN suppression) (NN proliferation)))))))) (, ,) (NP (NN induction) (NN cell) (NN apoptosis) (NN cell) (NN cycle) (NN arrest))) |ET| |BS|39:G04.299.139.160 41:A11 82:D12.644.360.024.342.300 86:D01.268.556.435 142:I01.880.604 155:G05.355.310 198:D13.444.308 351:A17.360 773:G04.299.134.109|ES| 2:1 5:1 9:1 19:1 89:1 94:1 115:1 251:1 299:1 307:1 399:1 601:1 602:1 639:1 666:1 736:1 1283:1 1487:1 2453:1 5620:1 5621:1
-1 	|BT| (S (NP (NN Exposure) (NN alternol)) (VP (VBD resulted) (NP (NP (NP (NP (JJ excessive) (JJ reactive) (NN oxygen) (NN specie)) (PRN (-LRB- -LRB-) (NP (NN ROS)) (-RRB- -RRB-))) (NP (NP (NN generation) (NN Jun) (JJ amino-terminal) (NN kinase)) (PRN (-LRB- -LRB-) (NP (NN JNK)) (-RRB- -RRB-)))) (, ,) (NP (NP (NP (JJ extracellular) (JJ signal-regulated) (NN kinase)) (PRN (-LRB- -LRB-) (NP (NN ERK1/2)) (-RRB- -RRB-))) (NN p38) (NN activation))))) |ET| |BS|116:D08.811.913.696.620.682.700.567.249.750 469:D08.811.913.696 477:D08.811.913.696.620.682.700.567.249 478:D08.811.913.696.620.682.700.567 506:F01.829.263.315 636:D01.339.431|ES| 2:1 10:1 14:1 19:1 225:1 470:1 594:1 1666:1 1707:1 1787:1 2353:1 2354:1 2355:1 2356:1 3982:1 4276:1 4594:1 4812:1 5622:1 5623:1 5624:1 5625:1
-1 	|BT| (S (ADVP (RB Finally)) (, ,) (NP (NN RNAseq) (NN analysis)) (VP (VBD indicated) (SBAR (S (NP (NP (NN p53) (NN signaling) (NN Lgr5)) (CC +) (NP (NN stem) (NN cell) (NN mouse))) (VP (VBN exposed) (NP (NNP AOM)) (ADVP (RB uniquely)) (VP (VBD upregulated) (PP (VBG following) (NP (JJ n-3) (NN PUFA) (CC +) (NN curcumin) (NN cotreatment))))))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 11:B01.050.150.900.649.865.635.505.500 69:G02.111.087.800 132:D02.172.080 308:A11.872 618:E02.186 692:D02.455.326.146.485.222.222 1308:D10.212.302.380.410|ES| 2:1 12:1 19:1 52:1 94:1 125:1 195:1 661:1 1106:1 1541:1 1929:1 1994:1 2652:1 3102:1 3510:1 4673:1 5626:1 5627:1 5628:1 5629:1
-1 	|BT| (S (NP (NP (JJ Forced) (NN inhibition) (NN p38) (NN MAPK) (NN activity) (JJ specific) (JJ pharmacological) (NN inhibitor) (NN SB203580) (NN p38) (NN MAPK) (NN gene) (NN knockdown)) (VP (VBG using) (NP (NP (JJ small-interfering) (NN RNA)) (PRN (-LRB- -LRB-) (NP (NN siRNA)) (-RRB- -RRB-))))) (VP (VBD counteracted) (NP (NN effect) (NN FL3)) (, ,) (S (VP (VBG demonstrating) (NP (NP (JJ chemopreventive) (NN action) (JJ related) (NN growth) (NN inhibition)) (NP (NP (JJ p38-dependent) (JJ caspase-3-dependent) (NN induction) (NN apoptosis)) (NP (JJ Oct4-expressing) (NNS CSCs)))))))) |ET| |BS|39:G04.299.139.160 43:F01.145.544 45:G07.700.320.249 117:D13.150.650.700 400:E05.393.335.500 556:C11.768.175 906:D08.811.277.656.262.500.126.350.300 1059:H01.158.703 1520:D08.811.913.696.620.682.700.567.843 1521:D12.776.260.655.500.300|ES| 2:1 9:1 10:1 14:1 19:1 75:1 89:1 102:1 103:1 350:1 351:1 380:1 399:1 419:1 464:1 515:1 527:1 540:1 736:1 809:1 1666:1 1946:1 1966:1 2013:1 3707:1 4883:1 5630:1 5631:1 5632:1 5633:1 5634:1 5635:1 5636:1
-1 	|BT| (SBAR (IN From) (S (NP (NN list)) (ADVP (RB differentially)) (VP (VBD expressed) (NP (NP (NP (NN gene) (VBN prioritized) (NN transcriptome) (NN profiling)) (, ,) (NP (NN Mmp7)) (, ,) (NP (NN S100a9)) (, ,) (NP (NP (NN Nppb) (NN Aldh1a3)) (NP (VBN defined) (NN key) (NN oncogene) (NN candidate)))) (VP (VBD downregulated) (NP (NN colon) (NN tumor) (NNP TA) (NN treatment))))))) |ET| |BS|6:G05.360.340.024.340 9:G05.360.340.024.340.375.500 51:C04.588.274.476.411.307.180 52:E02 937:D08.811.277.656.300.480.525.700.250 1286:E05.393.332|ES| 2:1 6:1 7:1 9:1 19:1 24:1 113:1 159:1 426:1 546:1 680:1 1139:1 1243:1 2148:1 5637:1 5638:1 5639:1 5640:1 5641:1 5642:1 5643:1 5644:1 5645:1
-1 	|BT| (S (ADVP (RB Furthermore)) (, ,) (NP (NP (NN exposure) (NN cell) (NN Japonicone) (NN A)) (VP (VBD caused) (NP (NN inactivation) (NN TNF-alpha-TAK1-IKK-NF-kappaB) (NN axis) (NN inhibition) (JJ TNF-alpha-stimulated) (NN NF-kappaB) (NN activity) (JJ nuclear) (NN translocation)))) (, ,) (VP (VBD followed) (NP (NP (NN downregulation) (NN NF-kappaB) (NN target) (NN gene)) (VP (VBN involved) (NP (NP (NP (NN cell) (NN apoptosis)) (PRN (-LRB- -LRB-) (NP (NP (NN Bcl-2)) (, ,) (NP (NN Bcl-xL)) (, ,) (NP (NN XIAP)) (, ,) (NP (NN TRAF2))) (-RRB- -RRB-))) (NP (NP (NN cell) (NN cycle) (NN growth)) (PRN (-LRB- -LRB-) (NP (NN cyclin) (NN D)) (, ,) (NP (NN c-Myc)) (-RRB- -RRB-)))))))) |ET| |BS|6:G05.360.340.024.340 39:G04.299.139.160 41:A11 43:F01.145.544 45:G07.700.320.249 54:G05.360.340.024.340.375.500.791.150 85:G02.111.087.225 210:D12.776.260.600 353:G04.299.134 463:C23.550.210.870 579:A02.835.232.834.151.383 789:D12.644.276.374.500.800 790:D12.644.276.374.750 1046:D12.644.360.262.150 1522:D12.644.360.024.500.750|ES| 2:1 9:1 10:1 14:1 19:1 69:1 89:1 94:1 102:1 103:1 158:1 160:1 334:1 399:1 595:1 601:1 714:1 743:1 774:1 824:1 1256:1 1314:1 1618:1 1953:1 2089:1 2506:1 2592:1 3130:1 4814:1 5646:1 5647:1 5648:1 5649:1 5650:1
-1 	|BT| (S (ADVP (RB Furthermore)) (, ,) (NP (NN hesperidin) (NN administration)) (VP (VBD restored) (SBAR (S (NP (NP (NP (NN glycogen) (NN synthase) (NN kinase-3) (NN beta)) (PRN (-LRB- -LRB-) (NP (NN GSK-3beta)) (-RRB- -RRB-))) (NN activity) (NN turn)) (VP (VBD prevented) (NP (NN accumulation) (NNS oncoproteins)) (NP (NP (NN beta-catenin)) (, ,) (NP (NN c-jun) (NN c-myc)))))))) |ET| |BS|23:D12.776.091.249 584:D12.776.624.664 1477:D03.383.663.283.266.450.252.500|ES| 2:1 10:1 14:1 19:1 60:1 66:1 92:1 334:1 399:1 455:1 1944:1 1972:1 2120:1 2575:1 3652:1 3653:1 4893:1 5356:1 5651:1 5652:1 5653:1
-1 	|BT| (S (ADVP (RB Furthermore)) (, ,) (PP (IN upon) (NP (NN TQ) (NN treatment))) (, ,) (NP (NN beta-catenin)) (VP (VP (VBD retained) (SBAR (S (NP (NN membrane) (NN c-myc)) (VP (VBD decreased) (NP (NN nucleus)))))) (, ,) (S (VP (VBN associated) (NP (VBN reduced) (NN cell) (NN proliferation) (NN villus)))))) |ET| |BS|23:D12.776.091.249 52:E02 183:G04.299.233.750 1104:A11.284.430.106 1344:A10.615|ES| 2:1 19:1 60:1 94:1 169:1 202:1 299:1 334:1 452:1 455:1 460:1 546:1 1577:1 1951:1 3622:1 3873:1 5654:1
-1 	|BT| (FRAG (ADVP (RB Here)) (, ,) (NP (NP (NN report) (ADJP (RB inversely) (JJ related)) (NN expression) (NN miR-137) (NN CAR) (JJ parental) (JJ doxorubicin-resistant) (NN neuroblastoma) (NN cell)) (, ,) (SBAR (WHADVP (WRB wherein)) (S (NP (NN miR-137)) (VP (VBD downregulated) (NP (JJ resistant) (NN cell))))))) |ET| |BS|41:A11 136:D02.455.426.559.847.562.050.200.175 137:C04.557.465.625.600.590.650.550 138:F01.829.263.500.320 139:J01.937.500.100|ES| 2:1 19:1 94:1 115:1 400:1 417:1 418:1 419:1 420:1 421:1 422:1 423:1 424:1 425:1 426:1 427:1
-1 	|BT| (S (ADVP (RB However)) (, ,) (VP (VBZ remains) (ADJP (JJ unknown) (SBAR (IN whether) (S (NP (NP (NN neoplasia)) (VP (VBN associated) (NP (NNP Pten) (ADJP (NN loss) (JJ dependent)) (JJ upstream) (NN IGF) (NN ligand) (NN supply) (FW vivo))))))))) |ET| |BS|8:C04 170:D27.720.470.480 581:D12.644.276.937|ES| 2:1 19:1 32:1 169:1 221:1 321:1 378:1 433:1 442:1 640:1 1835:1 1996:1 2182:1 3728:1 5655:1 5656:1
-1 	|BT| (S (ADVP (RB However)) (, ,) (NP (JJ combined) (NN effect) (NN mda-7) (NN sulindac)) (ADVP (RB previously)) (VP (VBN tested))) |ET| |BS|251:D02.455.426.559.847.486.875|ES| 2:1 19:1 75:1 164:1 433:1 869:1 1527:1 2988:1 5657:1
-1 	|BT| (S (NP (NN Hypermethylation) (NN miR-137) (NN promoter) (JJ negative) (NN regulation) (NN miR-137) (NN CAR)) (VP (VP (VBP contribute) (NP (NP (NN part)) (VP (VBD reduced) (NP (NN miR-137) (NN expression))))) (VP (VBD increased) (NP (NN CAR) (NN MDR1) (NN expression) (JJ doxorubicin-resistant) (NN neuroblastoma) (NN cell))))) |ET| |BS|41:A11 136:D02.455.426.559.847.562.050.200.175 137:C04.557.465.625.600.590.650.550 139:J01.937.500.100 142:I01.880.604|ES| 19:1 47:1 83:1 94:1 115:1 420:1 421:1 423:1 424:1 438:1 448:1 449:1 450:1 451:1 452:1 453:1
-1 	|BT| (NP (NP (NP (NN Immunohistochemistry) (NN beta-catenin)) (, ,) (NP (NN c-myc)) (, ,) (NP (NP (NN Ki-67) (NN TUNEL-staining)) (VP (VBN performed) (VP (VBP investigate) (NP (NP (NN TQ) (POS 's)) (NN effect) (JJ major) (JJ colorectal) (NN cancer) (NN pathway))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 23:D12.776.091.249 30:Z01.058.290.190.800 31:D08.811.520.224.800 143:E01.370.225.500.607.512 144:E05.393.475|ES| 2:1 17:1 18:1 19:1 60:1 75:1 383:1 454:1 455:1 456:1 457:1 458:1 459:1 460:1 461:1 462:1
-1 	|BT| (FRAG (PP (IN In) (NP (NN addition))) (, ,) (NP (NP (NN ERK5) (NN inhibition)) (VP (VBD increased) (NP (NP (NN response) (NN HCT116) (NN p53)) (CC +) (NP (: /) (CC +) (NN cell) (NN 5-FU)))) (, ,)) (VBD failed) (VB sensitize) (NP (NP (NN HCT116) (NN p53)) (: -)) (: /) (: -) (NP (NP (NN cell) (JJ cytotoxic) (NN effect) (JJ chemotherapeutic) (NN agent)) (, ,) (VP (VBG suggesting) (NP (NP (JJ p53-dependent) (NN axis)) (VP (VBG mediating) (NP (NN 5-FU) (NN sensitization))))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 30:Z01.058.290.190.800 31:D08.811.520.224.800 43:F01.145.544 560:D03.383.742.698.875.404 579:A02.835.232.834.151.383 660:D27.505.954.248 717:A11.251.210.190.380|ES| 2:1 19:1 47:1 75:1 88:1 94:1 103:1 244:1 468:1 494:1 566:1 728:1 761:1 1009:1 1457:1 1505:1 1762:1 2089:1 2308:1 5471:1 5658:1 5659:1 5660:1 5661:1
-1 	|BT| (S (PP (IN In) (NP (JJ intestinal) (JJ epithelial) (NN cell) (NN IEC-6) (NN colon) (NN cancer) (NN cell) (NN HCT-116))) (, ,) (NP (NN IL-6) (NN expression) (NN signaling)) (VP (VBN assessed) (NP (NP (NNP SHH) (NN inhibitor) (NN level) (JJ inflammatory) (NN mediator)) (, ,) (NP (NP (NN proliferation)) (, ,) (NP (NN apoptosis)) (, ,) (NP (NN tumorsphere) (NN formation))) (, ,) (NP (NP (NN tumorigenesis)) (VP (ADVP (RB also)) (VBN measured)))))) |ET| |BS|20:G03.495 32:C04.697.098.500 33:C04.697.098 39:G04.299.139.160 41:A11 47:A03.556.124 69:G02.111.087.800 75:A11.436 201:D12.644.276.374.465.224 228:E05.978 1523:E01.370.225.625.400 1524:E04.936.225.687.500|ES| 2:1 5:1 18:1 19:1 43:1 78:1 89:1 94:1 109:1 113:1 115:1 127:1 195:1 244:1 249:1 299:1 380:1 738:1 789:1 2430:1 3148:1 3351:1 3823:1 5662:1 5663:1 5664:1
-1 	|BT| (S (S (PP (IN In) (NP (NN mouse) (NN model))) (, ,) (NP (NN SHH) (NN inhibitor)) (ADVP (RB significantly)) (VP (VBD reduced) (NP (NP (NN tumor) (NN incidence) (NN multiplicity)) (, ,) (VP (VBD decreased) (NP (NP (NN expression) (NN IL-6)) (, ,) (NP (NN TNF-alpha)) (, ,) (NP (NN COX-2)) (, ,) (NP (NN STAT3)) (, ,) (NP (NN NF-kappaB)) (, ,)))) (VP (ADVP (RB significantly)) (VBD induced) (NP (NN apoptosis)))))) |ET| |BS|8:C04 11:B01.050.150.900.649.865.635.505.500 39:G04.299.139.160 82:D12.644.360.024.342.300 201:D12.644.276.374.465.224 210:D12.776.260.600 434:E05.318.308.985.525.375 789:D12.644.276.374.500.800 790:D12.644.276.374.750|ES| 2:1 7:1 19:1 52:1 72:1 76:1 89:1 115:1 124:1 202:1 244:1 251:1 380:1 412:1 452:1 714:1 1511:1 2775:1 2863:1 3148:1 5664:1
-1 	|BT| (S (PP (IN In) (NP (NN study))) (, ,) (VP (VBD demonstrated) (NP (NP (JJ simvastatin-induced) (NN G0/G1) (NN arrest)) (VP (VBG inducing) (NP (NN p21) (NN p27) (NN accumulation) (NN HepG2) (NN Hep3B) (NN cell)))))) |ET| |BS|41:A11 754:D02.455.426.559.847.638.400.900|ES| 2:1 19:1 94:1 131:1 244:1 602:1 1124:1 1135:1 1175:1 1864:1 2120:1 3481:1 4502:1 5665:1 5666:1
-1 	|BT| (S (PP (IN In) (NP (NN study))) (, ,) (VP (VBD identified) (NP (NP (JJ novel) (NN CEBPD) (NN activator)) (, ,) (NP (NP (LST (LS 1) (: -)) (-LRB- -LRB-) (JJ 2-hydroxy-5-methylphenyl) (-RRB- -RRB-) (NN -3-phenyl-1,3-propanedione)) (PRN (-LRB- -LRB-) (NP (NN HMDB)) (-RRB- -RRB-)))))) |ET| |BS|259:D12.776.395.240.150.500|ES| 2:1 10:1 14:1 19:1 131:1 244:1 623:1 861:1 891:1 5667:1 5668:1 5669:1 5670:1 5671:1
-1 	|BT| (S (ADVP (FW In) (FW vitro)) (, ,) (VP (NP (NN TQ)) (VP (VBD activated) (NP (NN GSK-3beta))) (, ,) (VP (VBD induced) (NP (JJ membranous) (NN localization) (NN beta-catenin))) (VP (VBD reduced) (NP (JJ nuclear) (NN c-myc) (NN expression))))) |ET| |BS|23:D12.776.091.249 1344:A10.615|ES| 2:1 19:1 60:1 115:1 163:1 216:1 244:1 412:1 452:1 455:1 460:1 1256:1 2484:1 3653:1 5672:1
-1 	|BT| (S (NP (NN Iso-3)) (VP (VBD induced) (NP (NP (NP (NN growth) (NN arrest) (NN cancer) (NN cell) (NN G0/G1)) (JJ concomitant)) (SBAR (S (NP (VBN increased) (NN p21) (NN p27) (NN expression)) (VP (VBD reduced) (NP (NP (NN cyclin) (NN E1)) (, ,) (NP (NN PCNA) (NN c-myc) (NN level))))))))) |ET| |BS|41:A11 45:G07.700.320.249 768:D12.776.660.740|ES| 2:1 18:1 19:1 47:1 94:1 102:1 115:1 249:1 412:1 452:1 455:1 602:1 743:1 1124:1 1135:1 1580:1 1681:1 2698:1 5666:1 5673:1
-1 	|BT| (S (NP (NN Isorhamnetin)) (VP (VBD inhibited) (NP (JJ AOM/DSS-induced) (JJ oncogenic) (NN c-Src) (NN activation) (NN beta-catenin) (JJ nuclear) (NN translocation)) (, ,) (S (VP (VBG promoting) (NP (NP (NP (NN expression) (JJ C-terminal) (NN Src) (NN kinase)) (PRN (-LRB- -LRB-) (NP (NN CSK)) (-RRB- -RRB-))) (, ,) (NP (JJ negative) (NN regulator) (NN Src) (NN family) (NN tyrosine) (NN kinase))))))) |ET| |BS|23:D12.776.091.249 122:C14.280.383 132:D02.172.080 279:D27.888.569.100 463:C23.550.210.870 1525:D08.811.913.696.620.682.725.800|ES| 2:1 10:1 14:1 19:1 60:1 97:1 115:1 225:1 235:1 365:1 449:1 470:1 881:1 953:1 1256:1 1618:1 2341:1 3674:1 3676:1 5018:1 5596:1 5674:1 5675:1
-1 	|BT| (S (NP (NN K-Ras) (NN mutation) (NN treatment) (NN outcome) (JJ colorectal) (NN cancer) (NN patient)) (VP (VBG receiving) (NP (JJ exclusive) (NN fluoropyrimidine) (NN therapy)))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 18:G05.365.590 50:M01.643 52:E02 164:E01.789.800|ES| 13:1 17:1 18:1 19:1 34:1 120:1 130:1 546:1 547:1 548:1 549:1 550:1
-1 	|BT| (NP (NP (NP (JJ K-ras) (NN mutation)) (NP (VBN assessed) (NN PCR) (NN mRNA) (NN egfr) (NN ligand) (JJ quantitative) (JJ real-time) (NN PCR)))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550 18:G05.365.590 111:D13.444.735.544 170:D27.720.470.480 257:E05.393.620.500.706 346:E05.393.620.500.706 448:E05.393.620.500|ES| 19:1 34:1 325:1 817:1 874:1 875:1 1121:1 1835:1 3823:1 5676:1
-1 	|BT| (NP (NP (NNS METHODS)) (: :) (S (NP (NP (NP (JJ Stable) (JJ transient) (NN RNA) (NN silencing) (NN GAST) (NN gene)) (VP (VBD induced) (NP (NP (JJ human) (NN tumor) (NN cell) (NN mouse)) (VP (VBG carrying) (NP (NP (JJ heterozygous) (NN Apc) (NN mutation)) (PRN (-LRB- -LRB-) (NP (NN APCDelta14)) (-RRB- -RRB-))))))) (, ,) (VP (VBP overexpress) (NP (NN progastrin)))) (VP (VBD amidated) (NP (JJ glycine-extended) (NN gastrin))))) |ET| |BS|3:C04.557.470.035.215.100 6:G05.360.340.024.340 8:C04 11:B01.050.150.900.649.865.635.505.500 18:G05.365.590 41:A11 42:G05.355.315.203.374 55:B01.050.150.900.649.801.400.112.400.400 156:G05.355.315.203.374.790 157:G05.380.383 168:E05.581 199:D06.472.317.413 200:D06.472.317.413 247:G01.374.676.530 1003:D12.125.481 1422:D13.444.735|ES| 2:1 7:1 9:1 10:1 14:1 19:1 34:1 36:1 52:1 94:1 100:1 104:1 280:1 412:1 515:1 565:1 671:1 676:1 745:1 786:1 850:1 2513:1 5677:1 5678:1 5679:1 5680:1 5681:1
-1 	|BT| (S (S (NP (NNP Mevalonate)) (VP (VBD decreased) (NP (NP (JJ simvastatin-induced) (NN AMPK) (NN activation)) (VP (VBD rescued) (NP (JJ phospho-STAT3) (NN Skp2) (NN expression) (NN HCC) (NN cell)))))) (, ,) (VP (VBD resulted) (NP (NN prevention) (NN G0/G1) (NN arrest) (NN inhibition) (NN p21) (NN p27) (NN accumulation)))) |ET| |BS|41:A11 43:F01.145.544 82:D12.644.360.024.342.300 104:C04.557.470.200.025.255 507:D12.776.157.743 754:D02.455.426.559.847.638.400.900 1526:D02.241.511.579|ES| 2:1 19:1 94:1 103:1 115:1 202:1 225:1 441:1 594:1 602:1 1124:1 1135:1 1474:1 1785:1 2120:1 4692:1 5665:1 5666:1 5682:1 5683:1 5684:1
-1 	|BT| (S (S (NP (NN miR-137) (NN overexpression)) (VP (VBD resulted) (NP (NP (NN downregulation) (NN CAR) (NN protein) (NN mRNA)) (PRN (-LRB- -LRB-) (PP (IN via) (NP (NN mRNA) (NN degradation))) (-RRB- -RRB-))))) (: ;) (S (VBN sensitized) (NP (JJ doxorubicin-resistant) (NN cell) (NN doxorubicin)) (-LRB- -LRB-) (VP (VP (VBN shown) (S (VP (VBN reduced) (NP (NN proliferation))))) (, ,) (VP (VBD increased) (NP (NN apoptosis))) (VP (VBD increased) (NP (JJ G2-phase) (NN cell) (NN cycle) (NN arrest))) (SINV (-RRB- -RRB-) (NP (VBD reduced) (FW vivo) (NN growth) (NN rate) (NN neuroblastoma) (NN xenograft)))))) |ET| |BS|7:D12.776 39:G04.299.139.160 41:A11 45:G07.700.320.249 85:G02.111.087.225 92:E04.936.764 93:A01.941.875 111:D13.444.735.544 136:D02.455.426.559.847.562.050.200.175 137:C04.557.465.625.600.590.650.550 139:J01.937.500.100 177:G04.299.134.109.500 178:G02.111.780|ES| 2:1 4:1 10:1 14:1 19:1 41:1 47:1 89:1 94:1 102:1 152:1 217:1 237:1 265:1 299:1 325:1 378:1 420:1 421:1 423:1 424:1 452:1 594:1 595:1 596:1 597:1 598:1 599:1 600:1 601:1 602:1
-1 	|BT| (S (NP (NN miR-137)) (VP (VBZ regulates) (SBAR (S (NP (JJ constitutive) (NN androstane) (NN receptor)) (VP (VBZ modulates) (NP (NN doxorubicin) (NN sensitivity) (JJ parental) (JJ doxorubicin-resistant) (NN neuroblastoma) (NN cell))))))) |ET| |BS|41:A11 136:D02.455.426.559.847.562.050.200.175 137:C04.557.465.625.600.590.650.550 138:F01.829.263.500.320|ES| 19:1 94:1 186:1 420:1 422:1 423:1 424:1 599:1 603:1 604:1 605:1 606:1 607:1
-1 	|BT| (S (ADVP (RB Moreover)) (, ,) (NP (NN inhibition) (NN SHP-1) (NN gene) (JJ small) (NN interference) (NN RNA)) (VP (VBD abolished) (SBAR (S (NP (NN ability) (NN evodiamine)) (VP (VBP inhibit) (NP (NP (NP (JJ IL-6-induced) (NN STAT3)) (PRN (-LRB- -LRB-) (NP (NP (NN Tyr)) (PRN (-LRB- -LRB-) (NP (CD 705)) (-RRB- -RRB-))) (-RRB- -RRB-))) (NN activation))))))) |ET| |BS|6:G05.360.340.024.340 30:Z01.058.290.190.800 31:D08.811.520.224.800 43:F01.145.544 82:D12.644.360.024.342.300 122:C14.280.383 201:D12.644.276.374.465.224 385:F02.784.629.131 634:D12.125.072.050.875 1206:D08.811.682.690.708.125.500 1422:D13.444.735|ES| 2:1 9:1 10:1 14:1 19:1 103:1 225:1 251:1 515:1 516:1 622:1 682:1 750:1 1300:1 1370:1 4232:1 4582:1 5577:1 5685:1 5686:1
